China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

Clinical trial NCT06868654 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06868654
Sponsor: GlaxoSmithKline
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2021-07-28
Primary completion: 2024-04-03
Enrollment: 72

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.